Loading
A phase 3 trial of tislelizumab in lung cancer, run by Yang Hong, now recruiting.
Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage II-III Non-small Cell Lung Cancer: A Phase III, Randomized, Multicenter, Prospective Study is a phase 3, randomised interventional study registered as NCT06598527 by Yang Hong, with a registry enrolment figure of 360 participants, started 2024-10-15 and due to reach its primary completion in 2027-01-30. Interventions recorded: Stereotactic body radiotherapy (SBRT); Tislelizumab; Chemotherapy. Conditions listed: Lung Cancer (NSCLC). Primary outcome: event-free survival. Lung eligibility wording from the registry: "Patients with cytologically/histologically diagnosed (by means of percutaneous lung aspiration biopsy, bronchoscopy, mediastinoscopy, etc". Sites: China. No results are recorded here; the registry entry is the source.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Resectable stage I to III non-small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.